Share Price and Basic Stock Data
Last Updated: February 2, 2026, 5:09 pm
| PEG Ratio | -6.63 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Concord Drugs Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹70.0 Cr and a share price of ₹70.0. Over recent periods, the company’s revenue has shown volatility, with quarterly sales peaking at ₹13.72 Cr in September 2022, then declining to ₹7.38 Cr by September 2023. This trend continues with projected sales of ₹36.93 Cr for the fiscal year ending March 2025, down from ₹51.31 Cr in March 2023. The trailing twelve months (TTM) revenue stood at ₹42.18 Cr, indicating a decline in operational performance compared to previous fiscal years. The company’s operating profit margin (OPM) was recorded at 10.03%, which reflects a challenging operational environment, particularly when compared to typical sector averages of around 15-20%. The sales decline and the fluctuating revenue base indicate potential challenges in market positioning and product demand, necessitating strategic reassessment to stabilize income streams and enhance growth prospects.
Profitability and Efficiency Metrics
Concord Drugs Ltd reported a net profit of ₹0.53 Cr for the quarter ending September 2023, which translated to an earnings per share (EPS) of ₹0.57. However, profitability has fluctuated significantly, with a notable dip into negative territory in December 2023, when the net profit fell to -₹0.24 Cr. The company’s return on equity (ROE) stood at 0.88%, which is relatively low compared to industry standards, indicating inefficiencies in generating shareholder returns. Additionally, the interest coverage ratio (ICR) of 2.05x suggests that while the company can meet its interest obligations, the margin is slim, highlighting potential liquidity concerns. The cash conversion cycle (CCC) has expanded to 332.82 days, indicating inefficiencies in managing working capital. These profitability metrics underscore the need for improved operational efficiency and cost management strategies to enhance overall financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Concord Drugs Ltd illustrates a total asset value of ₹58.58 Cr as of March 2025, with total borrowings at ₹14.89 Cr. The company has maintained a debt-to-equity ratio of 0.50x, which is in line with sector norms, suggesting a balanced approach to leveraging. Reserves have grown to ₹24.42 Cr, reflecting some capacity for reinvestment or cushioning against future operational challenges. However, the current ratio of 1.56 indicates that while the company can cover its short-term liabilities, the declining quick ratio of 0.59 points to potential liquidity constraints. The price-to-book value (P/BV) ratio of 0.91x suggests that the stock may be undervalued relative to its book value, which could attract value investors if the company can demonstrate a turnaround in performance. Overall, while the balance sheet shows some stability, there are areas of concern that need addressing to strengthen financial resilience.
Shareholding Pattern and Investor Confidence
As of September 2025, Concord Drugs Ltd has a diverse shareholding pattern, with promoters holding 54.39% and the public holding 45.61%. The increasing promoter stake from 49.00% in December 2022 to the current level indicates growing confidence from the company’s founders in its future potential. The number of shareholders has also increased to 4,718, reflecting growing public interest and potentially greater investor confidence. However, the absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) could be a red flag, as these entities typically provide stability and credibility to a company’s stock. The continued increase in public shareholding despite recent performance volatility suggests a speculative interest, but it also raises concerns about the sustainability of this confidence if the company fails to address its operational challenges effectively.
Outlook, Risks, and Final Insight
Looking ahead, Concord Drugs Ltd faces a dual-edged sword of opportunity and risk. On one hand, the low P/E ratio of 132 could indicate a potential for growth if the company can successfully navigate its operational challenges and improve profitability. On the other hand, persistent declines in revenue and profitability metrics raise significant concerns about the company’s future viability. The risks include ongoing operational inefficiencies, potential liquidity issues highlighted by the high cash conversion cycle, and the lack of institutional backing, which could hinder market confidence. To ensure a more favorable outlook, management must focus on strategic initiatives to enhance operational efficiency, stabilize revenues, and attract institutional investment. Without decisive action, the company may struggle to regain its footing in an increasingly competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,473 Cr. | 319 | 479/192 | 71.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,464.08 Cr | 1,084.45 | 46.05 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.72 | 13.53 | 11.54 | 8.79 | 7.38 | 12.62 | 14.47 | 6.35 | 11.84 | 10.77 | 7.96 | 13.38 | 10.07 |
| Expenses | 12.53 | 12.08 | 10.80 | 7.39 | 5.85 | 12.06 | 14.28 | 5.62 | 11.05 | 9.45 | 7.03 | 12.44 | 9.06 |
| Operating Profit | 1.19 | 1.45 | 0.74 | 1.40 | 1.53 | 0.56 | 0.19 | 0.73 | 0.79 | 1.32 | 0.93 | 0.94 | 1.01 |
| OPM % | 8.67% | 10.72% | 6.41% | 15.93% | 20.73% | 4.44% | 1.31% | 11.50% | 6.67% | 12.26% | 11.68% | 7.03% | 10.03% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.42 | 0.45 | 0.42 | 0.39 | 0.39 | 0.43 | 0.38 | 0.37 | 0.39 | 0.43 | 0.53 | 0.42 | 0.40 |
| Depreciation | 0.53 | 0.38 | 0.31 | 0.38 | 0.38 | 0.38 | 0.39 | 0.34 | 0.34 | 0.37 | 0.37 | 0.37 | 0.34 |
| Profit before tax | 0.24 | 0.62 | 0.01 | 0.63 | 0.77 | -0.25 | -0.58 | 0.02 | 0.07 | 0.52 | 0.03 | 0.15 | 0.27 |
| Tax % | 25.00% | 25.81% | -600.00% | 23.81% | 31.17% | -4.00% | -39.66% | 50.00% | 28.57% | 57.69% | 33.33% | 26.67% | 29.63% |
| Net Profit | 0.18 | 0.45 | 0.07 | 0.49 | 0.53 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 |
| EPS in Rs | 0.21 | 0.51 | 0.08 | 0.53 | 0.57 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 |
Last Updated: December 27, 2025, 11:33 am
Below is a detailed analysis of the quarterly data for Concord Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 10.07 Cr.. The value appears to be declining and may need further review. It has decreased from 13.38 Cr. (Jun 2025) to 10.07 Cr., marking a decrease of 3.31 Cr..
- For Expenses, as of Sep 2025, the value is 9.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.44 Cr. (Jun 2025) to 9.06 Cr., marking a decrease of 3.38 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.94 Cr. (Jun 2025) to 1.01 Cr., marking an increase of 0.07 Cr..
- For OPM %, as of Sep 2025, the value is 10.03%. The value appears strong and on an upward trend. It has increased from 7.03% (Jun 2025) to 10.03%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.40 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.42 Cr. (Jun 2025) to 0.40 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.34 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.37 Cr. (Jun 2025) to 0.34 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Jun 2025) to 0.27 Cr., marking an increase of 0.12 Cr..
- For Tax %, as of Sep 2025, the value is 29.63%. The value appears to be increasing, which may not be favorable. It has increased from 26.67% (Jun 2025) to 29.63%, marking an increase of 2.96%.
- For Net Profit, as of Sep 2025, the value is 0.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Jun 2025) to 0.19 Cr., marking an increase of 0.08 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.19. The value appears strong and on an upward trend. It has increased from 0.11 (Jun 2025) to 0.19, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.95 | 40.02 | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 42.18 |
| Expenses | 30.72 | 32.99 | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 37.98 |
| Operating Profit | 3.23 | 7.03 | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 4.20 |
| OPM % | 9.51% | 17.57% | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 10.21% | 9.96% |
| Other Income | 0.12 | 0.37 | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest | 1.78 | 2.72 | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.78 |
| Depreciation | 1.14 | 3.63 | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.42 | 1.45 |
| Profit before tax | 0.43 | 1.05 | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 0.97 |
| Tax % | 20.93% | 33.33% | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | 54.69% | |
| Net Profit | 0.34 | 0.70 | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.30 | 0.53 |
| EPS in Rs | 0.47 | 0.97 | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.30 | 0.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 105.88% | 150.00% | -90.86% | 100.00% | 28.12% | -19.51% | 893.94% | -51.52% | -44.03% | -52.81% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 44.12% | -240.86% | 190.86% | -71.88% | -47.64% | 913.45% | -945.46% | 7.50% | -8.78% | 24.24% |
Concord Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -6% |
| 3 Years: | -14% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -2% |
| 3 Years: | -43% |
| TTM: | 880% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 29% |
| 3 Years: | 26% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 10, 2025, 4:06 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.24 | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 | 10.00 |
| Reserves | 7.33 | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 | 24.42 |
| Borrowings | 17.31 | 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 | 14.89 |
| Other Liabilities | 12.80 | 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 | 12.87 |
| Total Liabilities | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
| Fixed Assets | 20.84 | 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 | 11.48 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 2.00 | 2.05 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 | 1.62 |
| Other Assets | 23.84 | 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 | 47.03 |
| Total Assets | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
Below is a detailed analysis of the balance sheet data for Concord Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 24.42 Cr.. The value appears strong and on an upward trend. It has increased from 24.11 Cr. (Mar 2025) to 24.42 Cr., marking an increase of 0.31 Cr..
- For Borrowings, as of Sep 2025, the value is 14.89 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 16.91 Cr. (Mar 2025) to 14.89 Cr., marking a decrease of 2.02 Cr..
- For Other Liabilities, as of Sep 2025, the value is 12.87 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.56 Cr. (Mar 2025) to 12.87 Cr., marking an increase of 5.31 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58.58 Cr. (Mar 2025) to 62.18 Cr., marking an increase of 3.60 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11.48 Cr.. The value appears to be declining and may need further review. It has decreased from 12.17 Cr. (Mar 2025) to 11.48 Cr., marking a decrease of 0.69 Cr..
- For CWIP, as of Sep 2025, the value is 2.05 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 2.05 Cr., marking an increase of 0.05 Cr..
- For Investments, as of Sep 2025, the value is 1.62 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.62 Cr..
- For Other Assets, as of Sep 2025, the value is 47.03 Cr.. The value appears strong and on an upward trend. It has increased from 42.79 Cr. (Mar 2025) to 47.03 Cr., marking an increase of 4.24 Cr..
- For Total Assets, as of Sep 2025, the value is 62.18 Cr.. The value appears strong and on an upward trend. It has increased from 58.58 Cr. (Mar 2025) to 62.18 Cr., marking an increase of 3.60 Cr..
Notably, the Reserves (24.42 Cr.) exceed the Borrowings (14.89 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.08 | -14.24 | -11.69 | -9.93 | -8.84 | -6.18 | -6.23 | -9.75 | -10.84 | -11.29 | -11.25 | -13.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 180.83 | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 |
| Inventory Days | 65.28 | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 |
| Days Payable | 140.64 | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 |
| Cash Conversion Cycle | 105.47 | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 285.41 | 332.82 |
| Working Capital Days | 55.48 | 68.04 | 113.14 | 4.00 | 79.27 | 102.33 | 103.37 | 140.30 | 112.48 | 145.12 | 126.56 | 134.22 |
| ROCE % | 7.15% | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 5.97% | 4.48% | 4.73% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Diluted EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Cash EPS (Rs.) | 1.77 | 2.03 | 2.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Revenue From Operations / Share (Rs.) | 45.24 | 44.92 | 55.91 |
| PBDIT / Share (Rs.) | 4.15 | 4.05 | 4.92 |
| PBIT / Share (Rs.) | 2.72 | 2.50 | 3.17 |
| PBT / Share (Rs.) | 0.69 | 0.62 | 1.34 |
| Net Profit / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| NP After MI And SOA / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| PBDIT Margin (%) | 9.16 | 9.01 | 8.79 |
| PBIT Margin (%) | 6.00 | 5.55 | 5.67 |
| PBT Margin (%) | 1.52 | 1.40 | 2.39 |
| Net Profit Margin (%) | 0.74 | 1.05 | 1.89 |
| NP After MI And SOA Margin (%) | 0.74 | 1.05 | 1.89 |
| Return on Networth / Equity (%) | 0.98 | 1.39 | 3.10 |
| Return on Capital Employeed (%) | 6.97 | 6.66 | 8.07 |
| Return On Assets (%) | 0.51 | 0.80 | 1.69 |
| Long Term Debt / Equity (X) | 0.03 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.50 | 0.49 | 0.50 |
| Asset Turnover Ratio (%) | 0.73 | 0.76 | 0.00 |
| Current Ratio (X) | 1.56 | 2.09 | 2.01 |
| Quick Ratio (X) | 0.59 | 1.02 | 1.08 |
| Inventory Turnover Ratio (X) | 1.88 | 2.09 | 0.00 |
| Interest Coverage Ratio (X) | 2.05 | 2.17 | 2.68 |
| Interest Coverage Ratio (Post Tax) (X) | 1.17 | 1.25 | 1.58 |
| Enterprise Value (Cr.) | 48.05 | 51.59 | 41.61 |
| EV / Net Operating Revenue (X) | 1.06 | 1.15 | 0.79 |
| EV / EBITDA (X) | 11.58 | 12.73 | 9.08 |
| MarketCap / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| Price / BV (X) | 0.91 | 1.04 | 0.80 |
| Price / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 |
After reviewing the key financial ratios for Concord Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.77. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.77, marking a decrease of 0.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 45.24. It has increased from 44.92 (Mar 24) to 45.24, marking an increase of 0.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 4.15. This value is within the healthy range. It has increased from 4.05 (Mar 24) to 4.15, marking an increase of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has increased from 2.50 (Mar 24) to 2.72, marking an increase of 0.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 0.69, marking an increase of 0.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For PBDIT Margin (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 10. It has increased from 9.01 (Mar 24) to 9.16, marking an increase of 0.15.
- For PBIT Margin (%), as of Mar 25, the value is 6.00. This value is below the healthy minimum of 10. It has increased from 5.55 (Mar 24) to 6.00, marking an increase of 0.45.
- For PBT Margin (%), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 10. It has increased from 1.40 (Mar 24) to 1.52, marking an increase of 0.12.
- For Net Profit Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 8. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 15. It has decreased from 1.39 (Mar 24) to 0.98, marking a decrease of 0.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.97. This value is below the healthy minimum of 10. It has increased from 6.66 (Mar 24) to 6.97, marking an increase of 0.31.
- For Return On Assets (%), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 5. It has decreased from 0.80 (Mar 24) to 0.51, marking a decrease of 0.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 0.50, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.76 (Mar 24) to 0.73, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.56, marking a decrease of 0.53.
- For Quick Ratio (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.59, marking a decrease of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 4. It has decreased from 2.09 (Mar 24) to 1.88, marking a decrease of 0.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.05. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 2.05, marking a decrease of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 3. It has decreased from 1.25 (Mar 24) to 1.17, marking a decrease of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 48.05. It has decreased from 51.59 (Mar 24) to 48.05, marking a decrease of 3.54.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.15 (Mar 24) to 1.06, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.58. This value is within the healthy range. It has decreased from 12.73 (Mar 24) to 11.58, marking a decrease of 1.15.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For Price / BV (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.91, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Concord Drugs Ltd:
- Net Profit Margin: 0.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.97% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.98% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.59
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 145 (Industry average Stock P/E: 46.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.5
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.249, R R District Telangana 501511 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Nagi Reddy | Chairman & Managing Director |
| Mr. S Manoj Kumar Reddy | Whole Time Director |
| Mr. S Koni Reddy | WholeTime Director & CFO |
| Mr. K Ramachandra Reddy | Independent Director |
| Ms. Sumeela Kasu | Independent Director |
| Mr. S Nagavenkata Hareesh | Independent Director |
FAQ
What is the intrinsic value of Concord Drugs Ltd?
Concord Drugs Ltd's intrinsic value (as of 04 February 2026) is ₹27.99 which is 63.65% lower the current market price of ₹77.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹77.0 Cr. market cap, FY2025-2026 high/low of ₹92.5/26.1, reserves of ₹24.42 Cr, and liabilities of ₹62.18 Cr.
What is the Market Cap of Concord Drugs Ltd?
The Market Cap of Concord Drugs Ltd is 77.0 Cr..
What is the current Stock Price of Concord Drugs Ltd as on 04 February 2026?
The current stock price of Concord Drugs Ltd as on 04 February 2026 is ₹77.0.
What is the High / Low of Concord Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Concord Drugs Ltd stocks is ₹92.5/26.1.
What is the Stock P/E of Concord Drugs Ltd?
The Stock P/E of Concord Drugs Ltd is 145.
What is the Book Value of Concord Drugs Ltd?
The Book Value of Concord Drugs Ltd is 34.4.
What is the Dividend Yield of Concord Drugs Ltd?
The Dividend Yield of Concord Drugs Ltd is 0.00 %.
What is the ROCE of Concord Drugs Ltd?
The ROCE of Concord Drugs Ltd is 4.73 %.
What is the ROE of Concord Drugs Ltd?
The ROE of Concord Drugs Ltd is 0.88 %.
What is the Face Value of Concord Drugs Ltd?
The Face Value of Concord Drugs Ltd is 10.0.